Journal
VACCINE
Volume 27, Issue 49, Pages 6854-6861Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.09.018
Keywords
Antibody response; NY-ESO-1; HER2
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- Cancer Translational Research, Project, Japan
- Cancer Research Institute, New York, USA
Ask authors/readers for more resources
Combination vaccines of the NY-ESC-1 protein complexed with cholesteryl pullulan (CHP), CHP-NY-ESO-1, and the truncated 146HER2 protein with CHP, CHP-HER2, were subcutaneously administered with the immuno-adjuvant OK-432 to eight esophageal cancer patients. Vaccination was well-tolerated. NY-ESO-1- and HER2-specific antibody responses were analyzed using the patients' sera and samples from previous single CHP-NY-ESO-1 or CHP-HER2 vaccine trial. The responses to NY-ESO-1 in the combination vaccine study were comparable to the single vaccine. For responses to HER2, there were fewer antibody responses in the combination vaccines. Although there were marked individual variations in the antibody responses to the NY-ESO-1 and HER2 antigens, the reaction patterns to these antigens were comparable within each patient. Antibodies to OK-432 were not augmented. Protein cancer vaccines targeting multiple antigens are feasible. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available